Range of eligible patients: CDEC talked over the uncertainty in the volume of people with reasonably significant to significant hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific experts consulted by CADTH indicated that some patients who will be labeled as obtaining gentle or average disease might have a significant https://dinahn163aaf3.wikiap.com/user